Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $1.00, $0.01 better than the analyst estimate of $0.99. Revenue for the quarter came in at $2.14 billion versus the consensus estimate of $2.07 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
- HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
- U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
